Four-Part Test

The Four-Part Test is a standardized federal framework adopted by New York State to verify that business activities qualify as legitimate research and development for tax credit purposes. To satisfy the test, an activity must have a qualified purpose, address technical uncertainty, utilize a systematic process of experimentation, and rely fundamentally on principles of the hard sciences.

The technical and statutory framework of the New York State Research and Development (R&D) tax credit is deeply integrated with federal standards, yet it is distinguished by unique state-level administrative requirements and industry-specific focuses. Central to this eligibility is Section 41 of the Internal Revenue Code (IRC), which New York has incorporated into its tax law to provide a consistent basis for defining qualified research. For businesses operating in New York, the ability to successfully claim these credits—whether through the Life Sciences Research and Development Tax Credit, the Qualified Emerging Technology Company (QETC) program, or the Excelsior Jobs Program—hinges on a granular understanding of the Four-Part Test. This regulatory standard serves as the primary mechanism for the New York State Department of Taxation and Finance (DTF) and Empire State Development (ESD) to distinguish between routine commercial operations and the high-risk, scientifically grounded innovation that the state intends to incentivize.

The Statutory Integration of IRC Section 41 and New York Tax Law

New York State does not maintain a wholly independent definition of research and development; instead, it relies on the experimental or laboratory sense established under federal IRC § 41(d) and § 174. The state’s tax code, specifically under Article 9-A for corporations and Article 22 for individuals and partnerships, adopts these federal benchmarks while imposing additional geographic restrictions—namely that the research must be conducted physically within the borders of New York State. This alignment provides a predictable landscape for taxpayers who are already familiar with federal R&D claims, but it requires a sophisticated approach to documentation that satisfies both federal and state-specific mandates.

The historical trajectory of New York’s R&D incentives reflects a deliberate shift toward fostering technology hubs, notably through legislation enacted in 1981 and 1982 that established the initial frameworks for research-related tax relief. Over subsequent decades, these laws have evolved into a multi-tiered system of credits that prioritize new businesses and emerging technologies. The state’s primary objective is to offset the initial capital drain experienced by startups in fields like biotechnology, genomics, and advanced manufacturing. By grounding state credits in the Four-Part Test, New York ensures that public funds are directed toward activities that advance the technological frontier rather than merely funding incremental or aesthetic improvements to existing products.

The First Pillar: The Qualified Purpose Test (Business Component Requirement)

The first element of the Four-Part Test necessitates that the research be undertaken for the purpose of discovering information that is intended to be applied to the development of a new or improved business component. Under IRC § 41(d)(2)(B), a business component is defined as any product, process, computer software, technique, formula, or invention which is to be held for sale, lease, or license, or used by the taxpayer in their trade or business.

For an activity to satisfy this pillar, the research must be directed toward improving the functionality, performance, reliability, or quality of the component. This functional requirement is a critical differentiator in New York audits. The state explicitly excludes activities related to style, taste, cosmetic design, or seasonal features. For instance, a software company that redesigns a user interface solely for visual appeal without enhancing the underlying processing speed or security protocols would fail the Qualified Purpose Test. Conversely, a medical device manufacturer attempting to miniaturize a sensor while maintaining its diagnostic accuracy is clearly pursuing a functional improvement that qualifies under the law.

Functional Outcomes and the “Shrink Back” Rule

In complex engineering or biological research, a project may fail the test as a whole but contain specific sub-components that meet the requirements. The “shrink back” rule, recognized by the IRS and subsequently New York authorities, allows a taxpayer to apply the Four-Part Test to a smaller subset of the project if the overall project fails. This ensures that genuine innovation at the component level is not disqualified by the failure of a larger, non-qualifying system. In the context of New York’s life sciences corridor, this is particularly relevant when a company is developing a comprehensive diagnostic platform; while the general software integration may be routine, the development of a specific novel reagent within that platform constitutes a qualifying business component.

The Second Pillar: The Elimination of Technical Uncertainty

The core of any R&D claim is the presence of technical uncertainty at the outset of the project. Uncertainty exists if the information available to the taxpayer does not establish either the capability or the method for developing or improving the business component, or the appropriate design of the component. This requirement effectively filters out routine engineering or reverse engineering of existing technologies where the path to the solution is already established in the public domain.

In New York, the Department of Taxation and Finance emphasizes that this uncertainty must be technical in nature, not commercial. A business may be uncertain whether a product will sell, but that does not qualify for the credit. The uncertainty must reside in the engineering or scientific challenge: “Can we build this?” or “How can we build this to meet these specific performance targets?”. For example, a biotechnology startup in New York City conducting Phase I clinical trials faces significant technical uncertainty regarding the efficacy and safety profile of a new molecular entity; this uncertainty is precisely what the R&D credit is designed to support.

The Third Pillar: The Process of Experimentation

The most rigorous and scrutinized element of the Four-Part Test is the “Process of Experimentation.” To satisfy this requirement, the taxpayer must demonstrate that substantially all of the activities constitute a process of experimentation for a qualified purpose. This involves a systematic evaluation of one or more alternatives to achieve a result where the capability, method, or design is uncertain at the beginning of the research.

This process must fundamentally rely on the scientific method, which includes:

1. Hypothesis Formulation: Identifying a technical challenge and proposing a solution.
2. Testing and Simulation: Conducting trials, using computer modeling, or building prototypes to evaluate the hypothesis.
3. Evaluation of Alternatives: Systematically comparing different designs or methods to identify the most effective one.
4. Refinement: Using the results of testing to modify the design and re-test until the uncertainty is eliminated.

New York guidelines are particularly strict regarding the documentation of this process. Simple trial and error without a structured framework or documentation of the alternatives being tested often leads to a denial of the credit during an audit. Auditors look for project records, lab notes, and failure reports, as the documentation of a “failed” experiment is often the strongest evidence that a genuine process of experimentation occurred.

The Fourth Pillar: Technological in Nature

The final requirement is that the research must be “technological in nature,” meaning the process of experimentation must fundamentally rely on the principles of the hard sciences. New York law specifies that these sciences include:

• Physical Sciences (Physics, Chemistry)
• Biological Sciences (Biology, Genomics, Pharmacology)
• Engineering
• Computer Science

Activities that rely on social sciences, economics, humanities, or business management do not qualify. This distinction is vital for New York’s diverse economy. While a financial services firm in Manhattan may innovate a new business strategy or a marketing model, those activities do not meet the technological requirement. However, if that same firm develops a proprietary high-frequency trading algorithm that requires advances in computer science and processor architecture, those specific technical efforts may qualify.

New York State R&D Incentive Programs: A Comparative Analysis

While the Four-Part Test provides the foundational criteria, New York offers several distinct programs that apply these rules differently based on industry and company size.

The Life Sciences Research and Development Tax Credit

The Life Sciences R&D Tax Credit is a specialized, fully refundable incentive designed for new business entities primarily engaged in fields such as biopharmaceuticals, genomics, medical devices, and pharmaceuticals. Administered by Empire State Development (ESD), this program is a cornerstone of the state’s strategy to attract early-stage biotech firms.

Feature	Life Sciences R&D Tax Credit
Eligibility	“New Business” in Life Sciences (Biopharma, Genomics, etc.)
Credit Rate	15% (10+ employees) or 20% (<10 employees)
Refundability	Fully Refundable (can be received as cash)
Annual Cap	$500,000 per year per taxpayer
Lifetime Cap	$1.5 million over three years
Qualified Expenses	Wages and Supplies (Excludes contract research)

A critical nuance of the Life Sciences credit is the exclusion of contract research. While the federal credit and many other state credits allow for a portion of payments to third-party labs or consultants, the New York Life Sciences credit explicitly prioritizes in-house employment. This is designed to ensure that the intellectual capital and high-paying scientific jobs remain within the state.

The Qualified Emerging Technology Company (QETC) Credit

The QETC R&D credit is broader in scope, covering a wide range of emerging technologies as defined in Public Authorities Law (PAL) § 3102-e. This credit is geared toward companies with total annual product sales of $10 million or less.

To qualify as a QETC, a company must meet one of two tests:

1. Primary Products or Services Test: More than 50% of the company’s receipts or expenses are attributable to emerging technologies.
2. R&D Ratio Test: The company’s ratio of research and development funds to net sales equals or exceeds the average ratio for all surveyed companies as determined by the National Science Foundation (NSF).

The NSF ratio is updated annually. For certification periods beginning in 2024, the required ratio is 4.3%, and for 2025, it is 4.5%. Unlike the Life Sciences credit, the QETC R&D credit is 18% of QREs in excess of a base amount and can be carried forward for up to 15 years, although it is generally not refundable.

The Excelsior Jobs Program R&D Credit

The Excelsior Jobs Program offers a suite of tax credits, including a robust R&D component. This program is typically utilized by larger firms or those making significant capital investments in the state. The credit is worth up to 50% of the federal R&D credit that relates to expenditures in New York, capped at 6% of the state QREs, or 8% for “green” projects.

The Excelsior program is unique because it requires a Consolidated Funding Application (CFA) and ongoing performance reporting to maintain eligibility. It is a performance-based incentive where credits are only issued after the taxpayer has reached specific job creation or investment targets and received a Certificate of Tax Credit from ESD.

Application of Credit Rates and Economic Impact

New York’s commitment to R&D is reflected in the tiered structures of its credit rates. For startups and small businesses, the higher rates and refundability options are designed to provide immediate liquidity.

Program	Credit Rate	Key Limitation
Life Sciences (<10 Emp)	20% of QREs	$500k Annual Cap
Life Sciences (10+ Emp)	15% of QREs	$500k Annual Cap
QETC R&D Credit	18% of QREs (over base)	$250k Annual Cap
Excelsior Jobs Program	6% of QREs	Performance-based
Excelsior Green Projects	8% of QREs	Must reduce greenhouse gasses

Statistical data from the PFM Group Consulting LLC report indicates that programs like Excelsior and the various QETC credits provide a significant return on investment (ROI) for the state. For every dollar of tax revenue foregone by the state, the indirect and induced economic effects, such as increased local spending and high-wage income taxes, can bring the total return close to parity, making these incentives a sustainable tool for economic development. In the 2020 tax year alone, QETC employment credits resulted in the retention or creation of approximately 1,574 high-tech jobs, with companies reporting over $55 million in associated R&D expenditures.

Local Revenue Office Guidance and the Audit Environment

The New York State Department of Taxation and Finance periodically issues Technical Services Bureau Memoranda (TSB-Ms) and Tax Bulletins to provide interpretive guidance on the R&D statutes. While these documents do not have the same force of law as statutes or regulations, they are the definitive guide for how state auditors will evaluate a claim.

Audit Protocols and the TAR System

The DTF operates a comprehensive Tax Audit Reporting (TAR) system designed to monitor and evaluate the progress of its audit division. In the context of R&D, auditors are trained to verify three main components:

1. Eligibility: Does the company meet the statutory definition of a “new business” or a “QETC”?
2. Qualified Research Activities (QRAs): Do the activities meet the Four-Part Test at the business component level?
3. Qualified Research Expenditures (QREs): Are the claimed wages, supplies, and expenses properly sourced to New York and directly related to the QRAs?

Audit guidelines emphasize that the taxpayer bears the burden of proof. Recordkeeping is paramount. New York requires that records be maintained for at least three years after the filing date, though a five-year retention policy is often recommended given the carry-forward provisions of the QETC credit.

Sales and Use Tax Exemptions for R&D Property

Beyond income tax credits, New York provides a significant sales and use tax exemption for tangible personal property used directly and predominantly in research and development. Under Tax Bulletin ST-773, property is exempt if it is used more than 50% of the time in R&D.

Item	Sales Tax Status	Requirement
Lab Equipment	Exempt	Used >50% in R&D
Supplies/Materials	Exempt	Consumed directly in R&D
CAD/CAM Software	Exempt	Used for R&D design
Clerical Furniture	Taxable	Not used directly in R&D
Utilities (Gas/Elec)	Exempt	Used 100% in R&D

This exemption applies at the point of purchase via Form ST-121 (Exempt Use Certificate). For utilities like gas and electricity to be exempt, they must be used directly and exclusively (100%) for research activities, often requiring a separate meter or an independent engineering survey to substantiate the usage.

The “New Business” Requirement: A Crucial Hurdle

For many of New York’s most generous credits, such as the refundable Life Sciences credit, the applicant must qualify as a “new business”. This is a anti-abuse measure designed to prevent established companies from simply restructuring to claim credits meant for startups.

A business is generally considered “new” if:

• It is a C-Corporation where less than 50% is owned by another New York taxpayer.
• It is not “substantially similar” in ownership and operation to a current or former New York taxpayer.
• It has not been a taxpayer in New York for more than five years.

This “newness” test applies regardless of whether the business is moving to New York from another state or starting from scratch within the state. It ensures that the state’s finite pool of $10 million in annual life sciences credits is allocated to growing innovators rather than established firms.

Practical Example: A Biotechnology Startup’s R&D Claim

To illustrate the application of these rules, consider a hypothetical New York-based startup, “GenomicVantage,” which has 7 employees and is developing a novel CRISPR-based tool for targeted gene therapy.

Part 1: Applying the Four-Part Test

1. Qualified Purpose: GenomicVantage is developing a new biological “tool” (a business component) intended for licensing to pharmaceutical companies. The goal is to increase the precision of gene edits, a functional performance improvement.

2. Elimination of Uncertainty: The team is uncertain about the optimal RNA sequence to guide the CRISPR enzyme to a specific genomic locus without causing “off-target” effects. This is a technical design uncertainty.

3. Process of Experimentation: The scientists design 50 variations of the guide RNA. They use computer modeling to simulate binding affinity and then perform lab trials on cell cultures to measure the actual edit rates. They document the failure of 48 sequences and the success of 2. This systematic trial and error satisfies the experimentation requirement.

4. Technological in Nature: The work is fundamentally based on biological and chemical sciences, satisfying the “hard science” requirement.

Part 2: Calculating the Credit

GenomicVantage incurs $600,000 in qualifying expenses during the 2024 tax year, consisting entirely of scientist salaries and lab supplies (reagents). All work is performed in their laboratory in Albany, NY.

Because they are a “new business” certified by ESD as a “qualified life sciences company” and have fewer than 10 employees, they qualify for the 20% credit rate.

$$Credit = \$600,000 \times 20\% = \$120,000$$

Since the company is pre-revenue and has no income tax liability, the $120,000 is fully refundable. GenomicVantage files Form CT-648 with their New York tax return, attaching the Certificate of Tax Credit received from ESD.

Recordkeeping and Audit Defense Strategies

Successfully passing a New York State R&D audit requires proactive, contemporaneous documentation. The state’s auditors increasingly look for a “nexus” between the scientific activity and the financial cost.

Contemporaneous Documentation vs. Reconstruction

The most common pitfall for New York businesses is attempting to reconstruct their R&D activities at the end of the year or, worse, when an audit notice arrives. State guidance emphasizes that documentation should be created at the time the expense is incurred.

Recommended records include:

• Time-Tracking Data: Detailed logs showing the percentage of time each employee spent on specific qualifying projects.
• Project Narrative Summaries: Documents updated quarterly that describe the technical challenges faced and the experiments conducted.
• Laboratory Notebooks: Dated records of experimental setups, observations, and results.
• Prototypes and Photographs: Visual evidence of the development stages of a physical product.

The Role of Form 6765

While New York has its own forms (e.g., CT-631 for QETC or CT-648 for Life Sciences), auditors frequently request the federal Form 6765 to ensure consistency. Discrepancies between federal and state claims regarding what constitutes a qualified research activity are a red flag for auditors. If a project is claimed for the federal credit but excluded from the state credit (or vice versa), the taxpayer must be prepared to explain the statutory reason for the difference—for example, out-of-state work that qualifies federally but not in New York.

The Impact of Remote Work on R&D Sourcing

The shift toward remote work has introduced a significant complexity into the sourcing of qualified wages. New York follows a “Convenience of the Employer” test for personal income tax, but for R&D tax credit purposes, the research must be conducted in New York.

If a New York-based company has a scientist working from home in Connecticut, the wages paid to that employee may not qualify as New York QREs, even if New York taxes that income under the convenience test. Businesses must carefully track the physical location where the research is performed to ensure they only claim expenses that meet the state’s geographic nexus requirements.

Statistical Trends and Future Outlook

The utilization of R&D credits in New York continues to track with the state’s broader economic objectives. The 2025 forecast for tax expenditures indicates a steady increase in the allocation for life sciences, mirroring the growth of the biotech corridor in Long Island and New York City.

Credit Type	2021 Actual ($M)	2022 Actual ($M)	2025 Forecast ($M)
QETC Employment Credit	3.8	3.5	5.0
QETC Capital Credit	3.3	1.3	1.8
Life Sciences R&D Credit	4.2	5.8	10.0
Investment Tax Credit (ITC)	94.2	141.0	180.0

The significant increase in the forecasted Life Sciences credit reflects the state’s aggressive posture in competing with other biotech hubs like Cambridge, MA, and San Francisco, CA. By offering a fully refundable credit with no carry-forward required, New York provides a superior cash-flow benefit for pre-revenue startups that are still years away from commercial profitability.

Final Thoughts

The Four-Part Test is more than a regulatory hurdle; it is the framework upon which New York’s innovation economy is built. For businesses, the R&D tax credit offers a powerful strategic tool to reduce the net cost of innovation, attract high-tier scientific talent, and reinvest capital into further research. However, the complexity of New York’s multi-tiered program structure—combined with the rigorous “new business” definitions and the exclusion of contract research in certain programs—demands a sophisticated compliance strategy.

To maximize these incentives while minimizing audit risk, companies must move beyond mere financial accounting and integrate their scientific and technical documentation into their tax reporting process. By documenting the elimination of technical uncertainty and the systematic process of experimentation as they occur, New York businesses can secure the credits they deserve and continue to drive the technological advancements that are vital to the state’s economic future. As legislative enhancements continue to expand these programs—such as the recent extension of the Excelsior Jobs Program through 2039—the importance of the Four-Part Test as the universal standard for innovation will only increase. For the professional peer in the business or legal sector, mastering this framework is essential for navigating the high-stakes environment of New York’s R&D tax landscape.